NCT03926143View on ClinicalTrials.gov

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

May 18, 2022

Study Completion Date

May 18, 2022

Conditions
Solid Tumors
Interventions
DRUG

BAY94-9343 (Anetumab ravtansine)

BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies

Trial Locations (7)

13385

Hôpital de la Timone - Marseille, Marseille

20162

ASST Grande Ospedale Metropolitano Niguarda, Milan

20892

National Cancer Institute - Maryland, Bethesda

37203

Sarah Cannon Cancer Center, Nashville

60637

University of Chicago, Chicago

75230

Mary Crowley Medical Research Center, Dallas

70-891

Samodzielny Publiczny Wojewodzki Szpital Zespolony, Szczecin-Zdunowo

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03926143 - A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies | Biotech Hunter | Biotech Hunter